Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC10A6 | Q3KNW5 | 1/20 | 0.47 |
| ▸ | VCAM1 | P19320 | 1/20 | 0.47 |
| ▸ | F2 | P00734 | 1/20 | 0.46 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.46 |
| ▸ | PRSS2 | P07478 | 1/20 | 0.46 |
| ▸ | PRSS3 | P35030 | 1/20 | 0.46 |
| ▸ | POLB | P06746 | 2/20 | 0.45 |
| ▸ | MAPT | P10636 | 2/20 | 0.45 |
| ▸ | THRB | P10828 | 1/20 | 0.45 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.44 |
| ▸ | CA1 | P00915 | 2/20 | 0.44 |
| ▸ | CA2 | P00918 | 2/20 | 0.44 |
| ▸ | MMP1 | P03956 | 1/20 | 0.44 |
| ▸ | MMP2 | P08253 | 1/20 | 0.44 |
| ▸ | MMP9 | P14780 | 1/20 | 0.44 |
| ▸ | MMP8 | P22894 | 1/20 | 0.44 |
| ▸ | MMP13 | P45452 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30305428 | 1.00 | SLC10A6 (0.47) | SLC10A6VCAM1F2PRSS1PRSS2 | |
| SCHEMBL4818765 | 0.86 | CA1 (0.51) | SLC10A6VCAM1F2PRSS1PRSS2 | |
| SCHEMBL10567889 | 0.85 | ALDH1A1 (0.47) | POLBMAPTTHRBTDP1L3MBTL1 | |
| SCHEMBL11398188 | 0.83 | TDP1 (0.56) | VCAM1POLBMAPTTDP1L3MBTL1 | |
| SCHEMBL4810290 | 0.82 | SLC10A6 (0.47) | SLC10A6VCAM1F2PRSS1PRSS2 | |
| SCHEMBL9620989 | 0.82 | TDP1 (0.57) | F2PRSS1PRSS2PRSS3POLB | |
| SCHEMBL7777718 | 0.82 | VCAM1 (0.49) | SLC10A6VCAM1F2PRSS1PRSS2 | |
| SCHEMBL10652008 | 0.80 | SLC10A6 (0.46) | SLC10A6VCAM1F2PRSS1PRSS2 | |
| SCHEMBL10565319 | 0.79 | ALDH1A1 (0.46) | SLC10A6VCAM1F2PRSS1PRSS2 | |
| SCHEMBL10569691 | 0.79 | CYP3A4 (0.41) | F2PRSS1PRSS2PRSS3POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12581252-B2 | Substituted pyrrolo[3,4-b]pyridines as PI3K-α inhibitors | RELAY THERAPEUTICS, INC. (US) | 2026-03-17 | — | — | US | disclosed |
| US-12219327-B2 | Substituted isoindolines as PI3K-alpha inhibitors | RELAY THERAPEUTICS, INC. (US) | 2025-02-04 | — | — | US | disclosed |
| US-20240287058-A1 | PI3K-ALPHA INHIBITORS AND METHODS OF USE THEREOF | RELAY THERAPEUTICS, INC. | 2024-08-29 | — | — | US | disclosed |
| US-20230353959-A1 | PI3K-ALPHA INHIBITORS AND METHODS OF USE THEREOF | RELAY THERAPEUTICS, INC. | 2023-11-02 | — | — | US | disclosed |
| US-20230353959-A1 | PI3K-ALPHA INHIBITORS AND METHODS OF USE THEREOF | RELAY THERAPEUTICS, INC. | 2023-11-02 | — | — | US | disclosed |
| CN-116261562-A | PI 3K-alpha inhibitors and methods of use thereof | 传达治疗有限公司 | 2023-06-13 | — | — | CN | disclosed |
| EP-4143196-A1 | PI3K-a INHIBITORS AND METHODS OF USE THEREOF | Relay Therapeutics, Inc. (US) | 2023-03-08 | — | — | EP | disclosed |
| WO-2021222556-A1 | PI3K-α INHIBITORS AND METHODS OF USE THEREOF | RELAY THERAPEUTICS, INC. (US) | 2021-11-04 | — | — | WO | disclosed |
| US-7414011-B2 | Phenylsulfonyl ureas, process for their preparation and their use as herbicides and plant growth regulators | HOECHST SCHERING AGREVO GMBH (US) | 2008-08-19 | — | — | US | disclosed |
| EP-1153016-B1 | PHENYLSULFONYL UREAS, METHODS FOR PRODUCING THEM AND THEIR USE AS HERBICIDES AND PLANT GROWTH REGULATORS | BAYER CROPSCIENCE AG (DE) | 2007-09-05 | — | — | EP | disclosed |
| US-4847294-A | Derivatives of 2-(substituted sulfamyl)-6-nitrobenzoic acids, useful as adjuncts to radiation therapy | MERCK & CO., INC. (US) | 1989-07-11 | — | — | US | disclosed |
| EP-0197386-B1 | 2-(SUBSTITUTED SULFAMYL) DERIVATIVES OF 6-NITROBENZOIC ACID, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | MERCK & CO. INC. (US) | 1988-11-02 | — | — | EP | disclosed |
| EP-0265806-A1 | 2-(Substituted sulfamyl)-6-nitrobenzoic acids, amides and esters thereof useful as adjuncts to radiation therapy | MERCK & CO. INC. (US) | 1988-05-04 | — | — | EP | disclosed |
| US-4731369-A | Amides and esters of 2-(N-(hydroxypiperidinoalkyl) and (hydroxypyrrolidinoalkyl)-aminosulfonyl)-6-nitrobenzoic acids useful as adjuncts to radiation therapy | MERCK & CO. INC. (US) | 1988-03-15 | — | — | US | disclosed |
| US-4694020-A | Derivatives of 2-(substituted sulfamyl)-6-nitrobenzoic acids and pharmaceutical compositions | MERCK & CO., INC. (US) | 1987-09-15 | — | — | US | disclosed |
| EP-0223124-A1 | Substituted aminosulfonyl 6-nitrobenzoic-esters or amides, processes for their preparation and pharmaceutical compositions containing them | MERCK & CO. INC. (US) | 1987-05-27 | — | — | EP | disclosed |
| US-4654369-A | Esters of 2-(substituted sulfamyl)-6-nitro-benzoic acid and pharmaceutical compositions | MERCK & CO., INC. (US) | 1987-03-31 | — | — | US | disclosed |
| US-4647588-A | 2-(substituted sulfamyl)-6-nitrobenzoic acid amides and pharmaceutical compositions | MERCK & CO., INC. (US) | 1987-03-03 | — | — | US | disclosed |
| EP-0197386-A1 | 2-(Substituted sulfamyl) derivatives of 6-nitrobenzoic acid, process for their preparation and pharmaceutical compositions containing them | MERCK & CO. INC. (US) | 1986-10-15 | — | — | EP | disclosed |
| US-4603133-A | Amides and esters of 2-[N-(morpholinoalkyl)aminosulfonyl]-6-nitrobenzoic acids and compositions useful as adjuncts to radiation therapy | MERCK & CO., INC. (US) | 1986-07-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12219327-B2 | Substituted isoindolines as PI3K-alpha inhibitors | PIK3CD, PIK3CB, PIK3R1 | SLC10A6 4443/4885VCAM1 2402/4885F2 4733/4885 |
| US-20240287058-A1 | PI3K-ALPHA INHIBITORS AND METHODS OF USE THEREOF | PIK3CA, PIK3CB, PIK3CD | SLC10A6 4584/4885VCAM1 1915/4885F2 4708/4885 |
| US-12581252-B2 | Substituted pyrrolo[3,4-b]pyridines as PI3K-α inhibitors | RORB, ROR1, RORA | SLC10A6 2945/4885VCAM1 3696/4885F2 4845/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.